ASCO 2019 | The ECOG-ACRIN E2810 study: pazopanib for patients with mRCC

Elizabeth Plimack • 3 Jun 2019

Genitourinary Cancer Kidney Cancer Pazopanib

ECOG-ACRIN E2810

Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center, Philadelphia, PA talks about The ECOG-ACRIN E2810 (NCT01575548) study that looks at pazopanib for patients with metastatic renal cell carcinoma (mRCC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Frontline immunotherapy for bladder cancer

Elizabeth Plimack • 15 Feb 2020

Exciting potential of pembrolizumab combined with axitinib for kidney cancer

Elizabeth Plimack • 8 Feb 2018

A bladder-sparing approach for muscle-invasive bladder cancer

Elizabeth Plimack • 8 Feb 2018

Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCC

Elizabeth Plimack • 1 Jun 2020

Related Videos

CABOSUN trial of cabozantinib - could it change how we treat frontline RCC?

Toni Choueiri • 18 Oct 2016

Erdafitinib for FGFR-mutated urothelial carcinoma

Arlene Siefker-Radtke • 19 Jun 2018

Upcoming therapies in the metastatic urothelial carcinoma space

Thomas Powles • 29 Nov 2018

Current status of VEGF inhibitor/immunotherapy combinations in RCC

Bradley McGregor • 16 Nov 2018